Two high-throughput screening assays for aberrant RNA-protein interactions in myotonic dystrophy type 1.
about
Studying a Drug-like, RNA-Focused Small Molecule Library Identifies Compounds That Inhibit RNA Toxicity in Myotonic DystrophyAlphaScreen-Based Assays: Ultra-High-Throughput Screening for Small-Molecule Inhibitors of Challenging Enzymes and Protein-Protein InteractionsMechanistic determinants of MBNL activityLomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects.Identification of small-molecule agonists of human relaxin family receptor 1 (RXFP1) by using a homogenous cell-based cAMP assay.Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules.Features of modularly assembled compounds that impart bioactivity against an RNA target.Aberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets?High-content screening identifies small molecules that remove nuclear foci, affect MBNL distribution and CELF1 protein levels via a PKC-independent pathway in myotonic dystrophy cell lines.Identification of Plant-derived Alkaloids with Therapeutic Potential for Myotonic Dystrophy Type IPrecise small-molecule recognition of a toxic CUG RNA repeat expansion.In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models.Rational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes myotonic dystrophy type 1.Rational design of chemical genetic probes of RNA function and lead therapeutics targeting repeating transcripts.Covalent small-molecule-RNA complex formation enables cellular profiling of small-molecule-RNA interactionsThe Emerging Role of RNA as a Therapeutic Target for Small Molecules.Development of pharmacophore models for small molecules targeting RNA: Application to the RNA repeat expansion in myotonic dystrophy type 1.
P2860
Q28830592-E774B874-B003-4D33-992E-597C360333CBQ30355791-035CF3D1-D791-4BFF-A785-7BF1E55CDCCAQ30830825-FC0C9659-CA5C-4554-8A59-4A60C442F085Q33698593-0C598F43-99F5-4BCE-89CB-7DE1E151FFADQ34501476-3525885E-56F9-444A-BA78-E4F9AF49F0B6Q34786164-231E337F-7CAB-4195-ADE7-944F6E4F5E06Q34986416-872DA582-FBC4-423F-89D5-1A848C24CFADQ35019375-6E59B21C-2553-4997-BAEE-25471E8DDBB5Q35030106-B22ED1DC-6C2D-4CA2-82D1-D54649B0B7E1Q36051366-C79A4579-BD60-4325-B172-7001E227CC67Q36219835-3B6E1F2E-F1F2-4ECA-B929-0AD8663398BCQ36392989-260FCC0D-A07E-46A6-B78F-C899996EB21BQ36484500-05847C22-8939-465A-806E-27509F08877DQ37360833-5DA95756-1A2D-4AD2-9128-EFBED966E116Q37421427-228CC948-DA12-4779-86FB-4F518740B86EQ38410949-632FC189-4E84-43DA-9137-33B1BC032C6EQ38434922-AC4EEBD7-818C-4A10-8F8A-ECBAC4D65BC3
P2860
Two high-throughput screening assays for aberrant RNA-protein interactions in myotonic dystrophy type 1.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Two high-throughput screening ...... in myotonic dystrophy type 1.
@ast
Two high-throughput screening ...... in myotonic dystrophy type 1.
@en
Two high-throughput screening ...... in myotonic dystrophy type 1.
@nl
type
label
Two high-throughput screening ...... in myotonic dystrophy type 1.
@ast
Two high-throughput screening ...... in myotonic dystrophy type 1.
@en
Two high-throughput screening ...... in myotonic dystrophy type 1.
@nl
prefLabel
Two high-throughput screening ...... in myotonic dystrophy type 1.
@ast
Two high-throughput screening ...... in myotonic dystrophy type 1.
@en
Two high-throughput screening ...... in myotonic dystrophy type 1.
@nl
P2093
P2860
P50
P1476
Two high-throughput screening ...... in myotonic dystrophy type 1.
@en
P2093
Catherine Z Chen
Charles A Thornton
Juan J Marugan
Krzysztof Sobczak
P2860
P2888
P304
P356
10.1007/S00216-011-5604-0
P407
P577
2012-01-05T00:00:00Z